Business
May 24, 2021
Poland could return to a normal monetary policy and start to reduce spending on state aid programmes in order to curb inflation, a government official said on Monday.
The country has spent significant amounts shoring up the economy during the pandemic, and this has contributed to a rise in inflation.
Polish CPI stood 4.3 percent at the end of April, according to the central bank. We are approaching the point where both monetary policy should be normalised and the scale of support for the economy should be withdrawn so that it does not increase inflation tendencies, Pawel Borys, head of the Polish Development Fund (PFR) told Rzeczpospolita daily on Monday.
Grzegorz Michałowski/PAP
Covid-19 vaccine production may start on an industrial scale at Polish biotech firm Mabion in the third quarter of this year, the head of the Polish Development Fund told the Money.pl portal on Wednesday. As far as I know, the transfer of production technology for these vaccines is currently ongoing and should be finished by June, Pawel Borys told the portal. If the test series are produced and accepted, then in the third quarter production can start on an industrial scale.
Mabion closed a deal with the Novavax company in March concerning technology transfer and technical production trials of a Covid-19 vaccine on a commercial scale. It was announced at the time that the technology transfer and verification process should be completed in the first half of 2021.
Poland's economic growth could reach up to 5 percent this year, but if the coronavirus restrictions are prolonged for a considerable time, GDP expansion may be as little as 2 percent, the head of the state-run development fund PFR, Pawel Borys, has said.
Novavax Deal With Mabion Boosts Poland’s Nascent Biotech Scene
Bloomberg 3/3/2021 Piotr Bujnicki and Konrad Krasuski
(Bloomberg) Poland’s fledgling biotechnology industry got an unexpected vote of confidence after Mabion SA won a deal with Novavax Inc. to potentially produce its future Covid-19 vaccine.
Popular Searches
Mabion will start commercial-scale production trials of Novavax shot and obtain access to the U.S. company’s technology, according to an agreement unveiled on Wednesday. Shares in the Warsaw-listed biotech company soared a record 89%.
“We hope that this is the first step toward building a significant production capacity of the vaccine in Poland,” said Mabion’s founder Maciej Wieczorek.
Poland strikes deal to produce Novavax COVID-19 vaccine metro.us - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from metro.us Daily Mail and Mail on Sunday newspapers.